New! A Major Revolution

The University of Texas MD Anderson Cancer Center’s Paolo Strati, MD, describes how the treatment of patients with CLL has ‘meaningfully changed’ over the last few years.

New! Update on Phase III Study of BTK Inhibitor for Diffuse Large B-Cell Lymphoma

An update on a phase III study (DBL3001) of ibrutinib in treatment-naïve diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), was recently released.

Read More

New! Blood Test Predicts Lymphoma Therapy Success Within Days

A blood test can predict which patients with diffuse large B-cell lymphoma (DLBCL) are likely to respond positively to initial therapy and which are likely to need more aggressive treatment.

Read More

New! Phospholipid Drug Conjugate Shows Promise Among Relapsed/Refractory DLBCL Patients

Positive interim results from a phase II clinical trial for CLR 131, an investigational radioiodinated phospholipid drug conjugate, in patients with diffuse large B-cell lymphoma (DLBCL) were recently released.

Read More